What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature

Hilal, Ziad; Schultheis, Beate; Hartmann, Fritz; Doğan, Aşkın; Çetin, Cem; Krentel, Harald; Schiermeier, Sven; Tempfer, Clemens B.

doi:10.21873/anticanres.11110

Cited by 7 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this data was not available in the present study as the analysis was retrospective. In the recurrent setting, similar results were reported with age [7] being associated with long-term survival. Another study of recurrent platinum-sensitive patients found a that over half of patients survived more than 5 years (52.8%) [36].…”

Section: Discussionsupporting

confidence: 81%

“…Another study of recurrent platinum-sensitive patients found a that over half of patients survived more than 5 years (52.8%) [36]. Multimodal treatment was also associated with long-term survival in different studies [7,37,38].…”

Section: Discussionmentioning

confidence: 99%

“…Inclusion criteria were: age from 18 to 75 years with incident advanced EOC or with recurrent EOC (either platinumresistant or platinum-sensitive) considered fit for surgery. Herein, long-term survivors were defined as patients who survived more than 5 years after HIPEC and CRS, irrespective of relapse [7].…”

Section: Patient Populationmentioning

confidence: 99%

See 2 more Smart Citations

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

Saux

Decullier

Gléhen

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objective: Despite a high response rate to first-line therapy, prognosis of epithelial ovarian carcinoma (EOC) remains poor. The objective of the present study was to evaluate the frequency of long-term survivors and to identify the prognostic factors associated with long-term survival in a French cohort of 566 patients. Methods: Patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for EOC in 13 French centers between 1991 and 2010 were included. Long-term survivors were defined as patients who survived more than 5 years after HIPEC and CRS, irrespective of relapse. Results: Seventy-eight long-term survivors were analyzed. The median follow-up was 74 months. Median age at the time of first HIPEC was 55.4 years (range [22.6-77.6]. Seven patients had advanced EOC and 71 patients had recurrent EOC (37 patients had platinum-resistant EOC and 32 had platinumsensitive disease). More than half of the long-term survivors had high-grade serous ovarian cancer (HGSOC). In univariate analysis, age 50 years (p ¼ .004), peritoneal cancer index (PCI) 8 (p ¼ .049) and CA-125 < 100 (p ¼ .02) were associated with long-term survival. There was a trend towards an association between higher CC-score and long-term survival (p ¼ .057). Conclusion: Age 50 years, PCI 8 and CA125 < 100 were associated with long-term survival in univariate analysis. There was a trend towards the significance of CC-score. Platinum-status was not associated with long-term survival.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

Saux

Decullier

Gléhen

et al. 2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Notably, in that study, 14% of the long‐term survivors had suboptimal RD, 11% had short platinum‐free intervals (<12 months), and 53% had recurrent disease. Hilal et al . also reported the characteristics of 360 cases of long‐term survivors of recurrent ovarian cancer through a PubMed literature search.…”

Section: Discussionsupporting

confidence: 71%

Clinical characteristics and prognostic inflection points among long‐term survivors of advanced epithelial ovarian cancer

Son

Kong

Paek

et al. 2017

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Regarding factors influencing the survival of patients, one study revealed that prolonged post progression survival of recurrent ovarian cancer patients was associated with post recurrence treatment, including secondary debulking surgery, favorable response to second-line therapy, and more than two chemotherapy regimens after the first recurrence (Soyama et al, 2017). Hilal (2016) reported that long-term survival of recurrent ovarian cancer was characterized by a young age, low tumor stage, long recurrence-free interval, and combined modality treatment with optimal cytoreductive surgery and systemic chemotherapy. Multiple retrospective…”

Section: Discussionmentioning

confidence: 99%

Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer

Hamontri

Tantitamit

2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: To determine the survival outcomes and prognostic factors of the patients with recurrent platinumresistant and refractory epithelial ovarian cancer (EOC), tubal, and peritoneal cancer. Methods: Women with recurrent platinum-resistant and refractory EOC, tubal and peritoneal cancer who received treatment at the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) between January 2010 and December 2019 were included. Demographic data, serum marker, surgical factors, pathological factors and response of treatment were reviewed. Kaplan-Meier was used to calculate survival outcome. Result: Forty patients were recruited in this study (platinum-resistant 24 patients and refractory 16 patients). The median survival times were 19 and 21 months in and platinum-resistant and platinumrefractory patients, respectively. There were no significant differences in overall survival according to age, comorbidity, tumor grading, primary treatment, and secondary surgery. However, histology of clear cell carcinoma may associate with increased risk of death. The median overall survival of patients with clear cell carcinoma, serous carcinoma, and others were 14.4, 22.9, and 32.2, respectively (p = 0.003). Conclusion: Almost 10 years, the survival rate of the patients in these group has not increased despite new treatments option. Novel strategies should be considered in National policy of the treatment for ovarian cancer in our country.

show abstract

What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature

Abstract: LTSROC are rare, with 360 cases described in the literature. LTSROC are characterized by young age, low tumor stage, long recurrence-free interval and combined modality treatment with optimal cytoreductive surgery and systemic chemotherapy.

Cited by 7 publications

References 15 publications

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

Clinical characteristics and prognostic inflection points among long‐term survivors of advanced epithelial ovarian cancer

Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer

Contact Info

Product

Resources

About